Design and synthesis of novel dihydropyridine alpha-1a antagonists

Bioorganic and Medicinal Chemistry Letters

Volumn 9, Issue 19, 1999, Pages 2843-2848

  Marzabadi, Mohammad R ^a   Hong, Xingfang ^a   Nagarathnam, Dhanapalan ^a   Miao, Shou Wu ^a   Chiu, George ^a   Wong, Wai C ^a   Wetzel, John M ^a   Fang, James ^a   Forray, Carlos ^a   Chen, Tsing B ^b   O'Malley, Stacey S ^b   Chang, Raymond S L ^b   Gluchowski, Charles ^a  

^a H LUNDBECK A S   (Denmark)

^b MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,4 DIHYDRO 2,6 DIMETHYL 4 (4 NITROPHENYL) 3,5 PYRIDINEDICARBOXYLIC ACID 3 AMIDE 5 [3 (4,4 DIPHENYL 1 PIPERIDINYL)PROPYL]AMIDE; 1,4 DIHYDRO 2,6 DIMETHYL 4 (4 NITROPHENYL) 3,5 PYRIDINEDICARBOXYLIC ACID [3 (4,4 DIPHENYL 1 PIPERIDINYL)PROPYL]AMIDE METHYL ESTER; AMLODIPINE; CALCIUM CHANNEL; DIHYDROPYRIDINE; PHENYLEPHRINE; PRAZOSIN; UNCLASSIFIED DRUG;

ALKYLATION; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CHEMICAL MODIFICATION; DOG; DRUG BIOAVAILABILITY; DRUG DESIGN; DRUG HALF LIFE; DRUG SYNTHESIS; ENANTIOMER; HUMAN; HUMAN TISSUE; NONHUMAN; PROSTATE;

ADRENERGIC ANTAGONISTS; ANIMALS; CALCIUM CHANNELS; DIHYDROPYRIDINES; DOGS; HUMANS; MALE; MOLECULAR STRUCTURE; PHENYLEPHRINE; PROSTATE; PROSTATIC HYPERPLASIA; PROTEIN BINDING; RATS; STEREOISOMERISM;

ANIMALIA; CANIS FAMILIARIS;

EID: 0033523676     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0960-894X(99)00484-9     Document Type: Article

References (19)

1. 1. Geller, J.; Kirschenbaum, A.; Lepor, H.; Levine, A. C. J. Clin. Endocrinol. Metabolism 1995, 80, 745.
2. 2. Monda, J. M.; Oesterling, J. E. Infect. Urology 1994, 47.
3. l antagonists under development for treating BPH include Rec 15/2739 (Testa, R.; Taddei, C.; Poggesi, E.; Destefani, C.; Cotecchia, S.; Hieble, J. P.; Sulpizio, A. C.; Naselsky, D.; Bergsma, D.; Ellis, C.; Swift, A.; Ganguly, S.; Ruffolo, R. R., Jr.; Leonardi, A. Pharmacol. Comm. 1995, 6, 79.) and SL 89.0591 (Kenny, B.; Collis, A.; Naylor, A.; Wyllie, M. Exp. Opin. Invest. Drugs 1995, 4(10), 915.).
4. l antagonists under development for treating BPH include Rec 15/2739 (Testa, R.; Taddei, C.; Poggesi, E.; Destefani, C.; Cotecchia, S.; Hieble, J. P.; Sulpizio, A. C.; Naselsky, D.; Bergsma, D.; Ellis, C.; Swift, A.; Ganguly, S.; Ruffolo, R. R., Jr.; Leonardi, A. Pharmacol. Comm. 1995, 6, 79.) and SL 89.0591 (Kenny, B.; Collis, A.; Naylor, A.; Wyllie, M. Exp. Opin. Invest. Drugs 1995, 4(10), 915.).
5. l antagonists under development for treating BPH include Rec 15/2739 (Testa, R.; Taddei, C.; Poggesi, E.; Destefani, C.; Cotecchia, S.; Hieble, J. P.; Sulpizio, A. C.; Naselsky, D.; Bergsma, D.; Ellis, C.; Swift, A.; Ganguly, S.; Ruffolo, R. R., Jr.; Leonardi, A. Pharmacol. Comm. 1995, 6, 79.) and SL 89.0591 (Kenny, B.; Collis, A.; Naylor, A.; Wyllie, M. Exp. Opin. Invest. Drugs 1995, 4(10), 915.).
6. l antagonists under development for treating BPH include Rec 15/2739 (Testa, R.; Taddei, C.; Poggesi, E.; Destefani, C.; Cotecchia, S.; Hieble, J. P.; Sulpizio, A. C.; Naselsky, D.; Bergsma, D.; Ellis, C.; Swift, A.; Ganguly, S.; Ruffolo, R. R., Jr.; Leonardi, A. Pharmacol. Comm. 1995, 6, 79.) and SL 89.0591 (Kenny, B.; Collis, A.; Naylor, A.; Wyllie, M. Exp. Opin. Invest. Drugs 1995, 4(10), 915.).
7. 4. Gong, G.; Chiu, G.; Gluchowski, C.; Brancheck, T. A.; Hartig, P.; Pettinger, W. A.; Forray, C. FACEB J. 1994, 8, A353. Forray, C.; Bard, J. A.; Wetzel, J. M.; Chiu, G.; Shapiro, E.; Tang, R.; Lepor, H.; Hartig, P. R.; Weinshank, R. L.; Branchek, T. A.; Gluchowski, C. Mol. Pharmacol. 1994, 45, 703.
8. 4. Gong, G.; Chiu, G.; Gluchowski, C.; Brancheck, T. A.; Hartig, P.; Pettinger, W. A.; Forray, C. FACEB J. 1994, 8, A353. Forray, C.; Bard, J. A.; Wetzel, J. M.; Chiu, G.; Shapiro, E.; Tang, R.; Lepor, H.; Hartig, P. R.; Weinshank, R. L.; Branchek, T. A.; Gluchowski, C. Mol. Pharmacol. 1994, 45, 703.
9. 5. (a) Ford, A. P. D. W.; Arredondo, N. F.; Blue, D. R., Jr.; Bonhaus, D. W.; Jasper, J.; Kava, M. S.; Lesnick, J.; Pfister, J. R.; Shieh, I. A.; Vimont, R. L.; Williams, T. J.; McNeal, J. E.; Stamey, T. A.; Clark, D. E. Molecular Pharm. 1996, 49, 209. (b) Shibata, K.; Foglar, R.; Horie, K.; Obida, K.; Sakamoto, A.; Ogawa, S.; Tsujimoto, G. Molecular Pharm. 1995, 48, 250.
10. 5. (a) Ford, A. P. D. W.; Arredondo, N. F.; Blue, D. R., Jr.; Bonhaus, D. W.; Jasper, J.; Kava, M. S.; Lesnick, J.; Pfister, J. R.; Shieh, I. A.; Vimont, R. L.; Williams, T. J.; McNeal, J. E.; Stamey, T. A.; Clark, D. E. Molecular Pharm. 1996, 49, 209. (b) Shibata, K.; Foglar, R.; Horie, K.; Obida, K.; Sakamoto, A.; Ogawa, S.; Tsujimoto, G. Molecular Pharm. 1995, 48, 250.
11. 6. Laz, T. M.; Forray, C.; Smith, K. E.; Bard, J. A.; Vaysse, P. J.-J.; Branchek, T. A.; Weinshank, R. L. Mol. Pharmacol. 1994, 46, 414.
12. 7. Wetzel, J. M.; Miao, S. W.; Forray, C.; Borden, L. A.; Branchek, T. A.; Gluchowski, C. J. Med. Chem. 1995, 38, 1579.
13. 8. Wong, W. C.; Chiu, G.; Wetzel, J. M.; Marzabadi, M. R.; Nagarathnam, D.; Wang, D.; Fang, J,; Miao, S.W.; Hong, X.; Forray, C.; Vaysse, P. J.-J.; Branchek, T. A.; Gluchowski, C.; Tang, R.; Lepor, H. J. Med. Chem. 1998, 41, 2643. See also: Nagarathnam, D.; Wetzel, J. M.; Miao, S. W.; Marzabadi, M. R.; Chiu, G.; Wong, W. C.; Hong, X.; Fang, J.; Forray, C.; Branchek, T. A.; Heydorn, W. E.; Chang, R. S. L.; Broten, T., Schorn, T. W.; Gluchowski, C. J. Med. Chem. 1998, 41, 5320.
14. 8. Wong, W. C.; Chiu, G.; Wetzel, J. M.; Marzabadi, M. R.; Nagarathnam, D.; Wang, D.; Fang, J,; Miao, S.W.; Hong, X.; Forray, C.; Vaysse, P. J.-J.; Branchek, T. A.; Gluchowski, C.; Tang, R.; Lepor, H. J. Med. Chem. 1998, 41, 2643. See also: Nagarathnam, D.; Wetzel, J. M.; Miao, S. W.; Marzabadi, M. R.; Chiu, G.; Wong, W. C.; Hong, X.; Fang, J.; Forray, C.; Branchek, T. A.; Heydorn, W. E.; Chang, R. S. L.; Broten, T., Schorn, T. W.; Gluchowski, C. J. Med. Chem. 1998, 41, 5320.
15. 9. (a) Arrowsmith, J. E.; Campbell, S. F.; Cross, P. E.; Stubbs, J. K.; Burges, R. A.; Gardiner, D. G., Blackburn, K. J. J. Med. Chem. 1986, 29, 1696. (b) Meredith, P. A.; Elliott, H. L. Clin. Pharmacokinet. 1992, 22, 22.
16. 9. (a) Arrowsmith, J. E.; Campbell, S. F.; Cross, P. E.; Stubbs, J. K.; Burges, R. A.; Gardiner, D. G., Blackburn, K. J. J. Med. Chem. 1986, 29, 1696. (b) Meredith, P. A.; Elliott, H. L. Clin. Pharmacokinet. 1992, 22, 22.
17. 10. O'Malley, S. S.; Chen, T. B.; Francis, B. E.; Gibson, R. E.; Burns, H. D.; DiSalvo, J.; Bayne, M. L.; Wetzel, J. M.; Nagarathnam, D.; Marzabadi, M. R.; Gluchowski, C.; Chang, R. S. L. Eur. J. Pharm. 1998, 348, 287.
18. 11. Marzabadi, M. R.; Hong, X.; Gluchowski, C. Tetrahedron Lett. 1998, 39, 5293.
19. 2O.